Avalo Therapeutics, Inc. Common Stock
AVTXAvalo Therapeutics, Inc. (AVTX) is a biotechnology company focused on developing innovative therapies for immune-inflammatory and specialized conditions. The company leverages its expertise in immunology and inflammation to advance treatments aimed at improving patient outcomes in chronic and rare diseases.
Company News
A comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.
Merus NV shares jumped 38.2% in pre-market trading after Genmab announced plans to acquire the company for $8 billion in an all-cash deal, adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Avalo Therapeutics announced the appointment of Kevin R. Lind to its Board of Directors, bringing over 20 years of leadership experience in biotechnology and capital markets. Lind previously led Longboard Pharmaceuticals to a $2.6 billion acquisition and will support Avalo's development of AVTX-009 for hidradenitis suppurativa.
Avalo Therapeutics announced participation in three investor conferences in September 2025, highlighting their lead asset AVTX-009, a monoclonal antibody targeting IL-1β for treating inflammatory diseases.
Avalo Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences to discuss its lead asset AVTX-009, a monoclonal antibody targeting inflammatory diseases.
